Amber Freed, Founder & CEO of SLC6A1 Connect, reflects on the lack of accurate diagnostic tools to support children with rare epilepsies. Freed expresses the need for federally mandated programs to fund the full genome sequencing of infants with rare epilepsies, to diagnose them more accurately and rapidly and speed up the process of drug discovery. This interview took place at the International Epilepsy Congress (IEC) 2023 in Dublin, Ireland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.